Seamount Financial Group Inc. Invests $259,000 in Edwards Lifesciences Corporation $EW

Seamount Financial Group Inc. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 3,312 shares of the medical research company’s stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Arlington Trust Co LLC raised its position in shares of Edwards Lifesciences by 1.2% during the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares during the period. Valeo Financial Advisors LLC lifted its stake in Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after acquiring an additional 142 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after acquiring an additional 145 shares in the last quarter. Dakota Wealth Management increased its holdings in Edwards Lifesciences by 2.5% in the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after buying an additional 146 shares during the last quarter. Finally, Leo Wealth LLC lifted its holdings in Edwards Lifesciences by 1.2% in the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after purchasing an additional 150 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Truist Financial boosted their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.61.

Edwards Lifesciences Price Performance

Shares of EW opened at $76.59 on Tuesday. The company’s 50-day moving average is $78.46 and its 200-day moving average is $76.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $44.97 billion, a PE ratio of 11.02, a PEG ratio of 3.71 and a beta of 1.05. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.